Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours

European Journal of Surgical Oncology

Volumn 30, Issue 10, 2004, Pages 1098-1103

  Aparicio, T ^a,b   Boige, V ^a   Sabourin, J C ^a   Crenn, P ^b   Ducreux, M ^a   Le Cesne, A ^a   Bonvalot, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Gastrointestinal stromal tumour; Prognostic factors; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DUODENUM TUMOR; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECTUM TUMOR; RECURRENCE RISK; SMALL INTESTINE TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH TUMOR; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GASTRECTOMY; INTESTINE TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECTUM; SMALL INTESTINE; STATISTICAL MODEL;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DUODENAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LINEAR MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RECTUM; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 13944280022     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.06.016     Document Type: Article

References (17)

1. G.D. Demetri M. von Mehren C.D. Blanke A.D. Van den Abbeele B. Eisenberg P.J. Roberts M.C. Heinrich D.A. Tuveson S. Singer M. Janicek J.A. Fletcher S.G. Silverman S.L. Silberman R. Capdeville B. Kiese B. Peng S. Dimitrijevic B.J. Druker C. Corless C.D. Fletcher H. Joensuu Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472-480
2. J. Verweij A. van Oosterom J.Y. Blay I. Judson S. Rodenhuis W. van der Graaf J. Radford A. Le Cesne P.C. Hogendoorn E.D. di Paola M. Brown O.S. Nielsen Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer 39 14 2003 2006-2011
3. J. Verveij P.G. Casali A. Le Cesne P. Reichard J.Y. Blay et al. Comparison of two doses of imatinib for the treatment of advanced gastro intestinal stromal tumour: Interim results of a randomised phase II study from the EORTC-STBSG, ISG, AGITG Proc ASCO 22 A 2003 3272
4. S. Singer B.P. Rubin M.L. Lux C.J. Chen G.D. Demetri C.D. Fletcher J.A. Fletcher Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 18 2002 3898-3905
5. J.P. Pierie U. Choudry A. Muzikansky B.Y. Yeap W.W. Souba M.J. Ott The effect of surgery and grade on outcome of gastrointestinal stromal tumors Arch Surg 136 4 2001 383-389
6. M. Miettinen W.H.L. El-Rifai L. Sobin J. Lasota Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review Hum Pathol 33 5 2002 478-483
7. R.P. DeMatteo J.L. Lewis D. Leung S.S. Mudan J.M. Woodruff M.F. Brennan Two hundred gastrointestinal stromal tumours. Recurrence patterns and prognostic factors for survival Ann Surg 231 2000 51-58
8. E.L. Kaplan P. Meir Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
9. E.H. Ng R.E. Pollock M.F. Munsell E.N. Atkinson M.M. Romsdahl Prognostic factors influencing survival in gastrointestinal leiomyosarcomas Ann Surg 215 1992 68-77
10. S.S. Mudan K.C. Conlon J.M. Woodruff J.J. Lewis M.F. Brennan Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection Cancer 88 1 2000 66-74
11. P.C. McGrath J.P. Neifeld W.J. Lawrence S. Kay J.S. Horsley J.A. Parker Gastrointestinal sarcomas. Analysis of prognostic factors Ann Surg 206 1987 706-710
12. C.D. Fletcher J.J. Berman C. Corless F. Gorstein J. Lasota B.J. Longley M. Miettinen T.J. O'Leary H. Remotti B.P. Rubin B. Shmookler L.H. Sobin S.W. Weiss Diagnosis of gastrointestinal stromal tumors: A consensus approach Hum Pathol 33 5 2002 459-465
13. M.J. Dougherty C. Compton M. Talbert W.C. Wood Sarcoma of the gastrointestinal tract Ann Surg 214 1990 569-574
14. F.C. Eilber G. Rosen C. Forscher S.D. Nelson F. Dorey F.R. Eilber Recurrent gastrointestinal stromal sarcomas Surg Oncol 9 2000 71-75
15. A. Cavalcanti S. Bonvalot D. Elias P. Terrier D. Vanel C. Lepechoux A. Le Cesne Intraperitoneal chemotherapy after complete resection of peritoneal sarcomatosis: Results of a monocentric randomized study Eur J Cancer 37 2001 86
16. R.P. DeMatteo The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571) Ann Surg Oncol 9 9 2002 831-839
17. C.L. Scaife K.K. Hunt R.S. Benjamin M.A. Burgess L.L. Chen J. Trent A.K. Raymond J.N. Cormier P.W. Pisters R.E. Pollock B.W. Feig Is there a role for surgery in patients with unresectable cKit+gastrointestinal stromal tumours treated with imatinib mesylate? Am J Surg 186 6 2003 665-669